| Literature DB >> 28493406 |
Abstract
Beta-hydroxy-beta-methylbutyrate (HMB) is a metabolite of the essential amino acid leucine that has been reported to have anabolic effects on protein metabolism. The aims of this article were to summarize the results of studies of the effects of HMB on skeletal muscle and to examine the evidence for the rationale to use HMB as a nutritional supplement to exert beneficial effects on muscle mass and function in various conditions of health and disease. The data presented here indicate that the beneficial effects of HMB have been well characterized in strength-power and endurance exercise. HMB attenuates exercise-induced muscle damage and enhances muscle hypertrophy and strength, aerobic performance, resistance to fatigue, and regenerative capacity. HMB is particularly effective in untrained individuals who are exposed to strenuous exercise and in trained individuals who are exposed to periods of high physical stress. The low effectiveness of HMB in strength-trained athletes could be due to the suppression of the proteolysis that is induced by the adaptation to training, which may blunt the effects of HMB. Studies performed with older people have demonstrated that HMB can attenuate the development of sarcopenia in elderly subjects and that the optimal effects of HMB on muscle growth and strength occur when it is combined with exercise. Studies performed under in vitro conditions and in various animal models suggest that HMB may be effective in treatment of muscle wasting in various forms of cachexia. However, there are few clinical reports of the effects of HMB on muscle wasting in cachexia; in addition, most of these studies evaluated the therapeutic potential of combinations of various agents. Therefore, it has not been possible to determine whether HMB was effective or if there was a synergistic effect. Although most of the endogenous HMB is produced in the liver, there are no reports regarding the levels and the effects of HMB supplementation in subjects with liver disease. Several studies have suggested that anabolic effects of HMB supplementation on skeletal muscle do not occur in healthy, non-exercising subjects. It is concluded that (i) HMB may be applied to enhance increases in the mass and strength of skeletal muscles in subjects who exercise and in the elderly and (ii) studies examining the effects of HMB administered alone are needed to obtain conclusions regarding the specific effectiveness in attenuating muscle wasting in various muscle-wasting disorders.Entities:
Keywords: Cachexia; Exercise; HMB; Leucine; Sarcopenia; Supplements
Mesh:
Substances:
Year: 2017 PMID: 28493406 PMCID: PMC5566641 DOI: 10.1002/jcsm.12208
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.910
Figure 1Pathways of HMB synthesis and catabolism HMB, beta‐hydroxy‐beta‐methylbutyrate; KIC, alpha‐ketoisocaproic acid; HB, beta‐hydroxybutyrate; HMG‐CoA, 3‐hydroxy‐3‐methyl‐glutaryl‐CoA. 1, BCAA aminotransferase; 2, BCKA dehydrogenase; 3, KIC dioxygenase; 4, glutamine synthetase; 5, alanine aminotransferase.
Figure 2Suggested mechanisms for the favourable effects of HMB supplementation on skeletal muscle.
Human studies that report beneficial effects of beta‐hydroxy‐beta‐methylbutyrate in exercise
| Study design | Benefits | Reference |
|---|---|---|
| Untrained individuals, HMB (1.5 or 3 g/day), resistance training for 3 or 7 weeks | ↑ muscle mass and strength, ↓ muscle damage | Nissen |
| Untrained men, HMB (3 or 6 g/day), resistance training for 8 weeks | ↑ muscle mass and strength, ↓ muscle damage | Gallagher |
| Untrained individuals, HMB (3 g/day), resistance training for 8 weeks | ↑ muscle mass and strength, ↓ muscle damage | Jowko |
| Recreationally resistance‐trained men, HMB (3 g) before lower body resistance exercise | Combination of HMB and cold water immersion after exercise improved performance recovery | Gonzalez |
| Strength‐trained and power‐trained individuals, HMB (3 g/day) and ATP (400 mg/day), resistance training for 8 weeks | ↑ LBM and strength | Lowery |
| Volleyball players, HMB (3 g/day) for 7 weeks | ↑ muscle mass and strength, ↑ anaerobic performance | Portal |
| Non‐resistance‐trained men, amino acid‐based formula containing HMB, heavy resistance training for 12 weeks | ↑ muscle mass and strength, ↓ muscle damage | Kraemer |
| Non‐resistance‐trained men, HMB (3 g/day) + KIC (0.3 g/day) for 14 days prior to a single bout of heavy resistance exercise | ↓ muscle damage | Van Someren |
| Volunteers running at least 48 km/week, HMB (3 g/day) for 6 weeks prior to a prolonged run (20 km) | ↓ muscle damage | Knitter |
| Cyclists, HMB (3 g/day) for 2 weeks | ↑ aerobic performance | Vukovich and Dreifort |
| Recreationally active subjects, HMB (3 g/day), ergometer tests over a 4 week period | ↑ aerobic performance | Robinson |
| Active college students, HMB (3 g/day), exercise for 5 weeks | ↑aerobic performance | Lamboley |
| Rowers, HMB (3 g/day) for 12 weeks | ↑ LBM and aerobic performance | Durkalec‐Michalski and Jeszka |
| Athletes practicing wrestling, judo, jiu‐jitsu, karate or rowing; HMB (3 g/day) for 12 weeks | ↑ LBM and aerobic performance | Durkalec‐Michalski and Jeszka |
| Trained and untrained individuals, HMB (3 g/day), resistance training for 4 weeks | ↑ LBM and muscle strength regardless of gender and training status. | Panton |
| Resistance‐trained men, HMB (3 g/day), resistance training for 12 weeks | ↑ LBM and muscle strength | Wilson |
| Resistance‐trained men, HMB (3 g) before high‐volume resistance exercise | ↓ muscle damage and improved recovery | Wilson |
| Untrained individuals, HMB (3 g/day), high intensity training for 4 weeks | ↑ physical working capacity | Miramonti |
LMB, lean body mass.
Human studies not supporting beneficial effects of beta‐hydroxy‐beta‐methylbutyrate in exercise
| Study design | Result | Reference |
|---|---|---|
| Non‐resistance‐trained subjects, HMB (40 mg/kg /day) for 6 days before maximal isokinetic exercise of elbow flexors | No beneficial effect on muscle soreness, arm girth, and torque measures | Paddon‐Jones |
| Resistance‐trained men, HMB (0.3 or 6 g/day), resistance training for 28 days | No beneficial effect on muscle strength and body composition | Kreider |
| Rugby players, HMB (3 g/day) for 6 weeks | No beneficial effect on aerobic and anaerobic ability | O'Connor and Crowe |
| Rugby players, HMB (3 g/day) for 6 weeks | No beneficial effect on muscle strength and endurance | O'Connor and Crowe |
| Resistance‐trained athletes, HMB (3 g/day) for 6 weeks | No beneficial effect on muscle strength, body composition, and markers of muscle damage | Slater |
| Football players, HMB (3 g/day) for 4 weeks | No beneficial effect on muscle strength and body composition | Ransone |
| Resistance‐trained subjects, HMB (3 g/day) for 9 weeks | No beneficial effect on body composition | Thomson |
| Football players, HMB (3 g/day) for 10 days | No beneficial effect on anaerobic power and creatine kinase and myoglobin in blood | Hoffman |
| Recreational exercisers, HMB (3 g/day) + KIC (0.3 g/day) for 11 days before downhill running | No benefits on indices of muscle damage | Nunan |
Effects of beta‐hydroxy‐beta‐methylbutyrate on muscle in elderly
| Study design | Effects of HMB | Reference |
|---|---|---|
| Animal studies | ||
| Rats, 20 months of age, HMB and β‐alanine supplementation (equivalent to human doses of 3 and 2.4 g per day, respectively) for 8 weeks | No significant effect on muscle mass, force or fatigability; ↓ expression of MuRF1 | Russ |
| Mice, 19 months of age, HMB (514 mg/kg) or β‐alanine (411 mg/kg) supplementation for 8 weeks | ↓ decline in muscle function | Vallejo |
| Rats, 34 months of age, hindlimb suspension for 2 weeks and reload for 2 weeks, HMB (340 mg/kg/day) orally | ↓ fibre area (in plantaris and soleus muscles) | Hao |
| Rats, 34 months of age, hindlimb suspension for 2 weeks and reload for 2 weeks, HMB (340 mg/kg/day) orally for 35 days | ↑ muscle mass, fibre cross‐sectional area and proliferation of stem cells during the reloading period | Alway |
| Human studies | ||
| HMB/Arg/Lys mixture (2 g/5 g/1.5 g per day) for 1 year | ↑ lean tissue mass and protein turnover | Baier |
| Bed‐ridden subjects, HMB (2 g/day) for 2 or 4 weeks | ↓ urinary urea nitrogen excretion | Hsieh |
| HMB (3 g/day) and exercise for 8 weeks | ↑ body fat loss | Vukovich |
| HMB/Arg/Lys mixture (2/5/1.5 g per day) for 12 weeks | ↑ limb circumference, leg and handgrip strength; ↑ whole body protein synthesis | Flakoll |
| HMB/Arg/Lys mixture (2/5/1.5 g per day) for 1 year | ↑ muscle mass, ↑ muscle strength only when vitamin D status was adequate | Fuller |
| HMB/Arg/Gln mixture for 2 weeks | ↑ collagen synthesis in muscle | Williams |
| HMB (1.5 g/day) + mild fitness programme for 8 weeks | ↑ muscle strength, ↑ physical performance parameters | Berton |
| HMB (3 g/day), bed rest for 10 days followed by resistance training for 8 weeks | HMB supplementation preserves muscle mass during bed rest | Deutz |
| HMB (3 g/day) for 24 weeks, both exercise and non‐exercise groups | ↑ muscle strength, no difference between exercising and non‐exercising groups | Stout |
Effects of beta‐hydroxy‐beta‐methylbutyrate under in vitro conditions of skeletal muscle atrophy
| Model | Effects of HMB | Reference |
|---|---|---|
| Murine myotubes exposed to HMB (50 μM) and PIF | ↓ depression of protein synthesis | Eley |
| Murine myotubes exposed to HMB (50 μM) and PIF | ↓ protein degradation and proteasome activity | Smith |
| Murine myotubes exposed to HMB (50 μM) and PIF, LPS, or angiotensin II | ↓ proteasome activity | Mirza |
| Murine myotubes exposed to HMB (50 μM) and LPS, TNF‐α, IFN‐γ, or angiotensin II | ↓ proteolysis, ROS formation and caspase activation | Eley |
| Murine myotubes exposed to HMB (50 μM) and LPS | ↓ protein degradation and caspase activation | Russell and Tisdale |
| Murine myotubes exposed to HMB (50 μM) and dexamethasone | ↓ protein degradation, ↓ expression of atrogin‐1 and MuRF1, ↓ reduction of myotube size | Aversa |
| Murine myotubes exposed to HMB (10 mM) and myostatin | ↓ fibre atrophy | Mobley |
| Rat L6 myotubes exposed to HMB (25 μM) and dexamethasone | ↓ lysosomal proteolysis induced by dexamethasone | Girón |
PIF, proteolysis‐inducing factor; LPS, lipopolysaccharides.
Effects of beta‐hydroxy‐beta‐methylbutyrate in animal models of muscle wasting
| Study design | Effects | Reference |
|---|---|---|
| Rats, AH‐130 ascites hepatoma, HMB‐enriched chow for 24 days | ↓ body weight and muscle loss | Aversa |
| Rats, Walker 256 tumour, HMB (320 mg/kg) by p.o. gavage | ↑ survival time | Caperuto |
| Mice, MAC 16 tumour, HMB (0.25 g/kg) by p.o. gavage for 4 days | ↓ body weight loss | Mirza |
| Rats, Walker 256 tumour, HMB (76 mg/kg) by p.o. gavage for 8 weeks | ↓ tumour weight, ↓ NF‐κB signalling, ↑ glycogen content in liver and muscle | Nunes |
| Mice, MAC 16 tumour, HMB (0.25 g/kg) or EPA (0.6 g/kg), or both by p.o. gavage for 8 days | ↓ muscle protein degradation and proteasome activity in all groups compared to controls, ↑ protein synthesis in HMB group | Smith |
| Rats, endotoxin (5 mg/kg i.p.), HMB (0.5 g/kg) via osmotic pump for 24 hours | ↓ proteolysis and proteasome activity in muscle | Kovarik |
| Rats, monolateral hindlimb immobilization or dexamethasone treatment, leucine (2.7 g/kg/day) or HMB (0.6 g/kg/day) orally for 1, 2, 3 or 7 days | No effect of on muscle mass and fibre cross‐sectional area in both models, ↓ expression of Mafbx/Atrogin after dexamethasone. Leucine had favourable effects on most of the parameters. | Baptista |
| Mice, Duchenne muscular dystrophy model (mdx mice), diet with added creatine, linoleic acid, alpha‐lipoic acid or HMB (individually and in combination) and exercise for 8 weeks | ↓ muscle loss and grip strength fatigue, ↑ grip strength | Payne |
| Rats, dexamethasone and co‐administration of HMB (320 mg/kg/day orally) for 21 days | ↓ the loss of body weight, lean mass and reduction of fibre cross‐sectional area | Girón |
| Rats, co‐administration of dexamethasone and HMB (150 or 600 mg/kg/day orally) for 5 days | ↓ muscle loss and damage and reduction in grip strength, ↓ MuRF1 expression | Noh |
| Mice, calorie restricted (−30%) and exercise, HMB (0.5 g/kg orally) for 6 weeks | Greater grip strength, gastrocnemius mass and fibre cross‐sectional area. No atrogin‐1 expression while elevation in controls. | Park |
EPA, eicosapentaenoic acid.
Effects of beta‐hydroxy‐beta‐methylbutyrate in humans with muscle‐wasting disorder
| Origin of muscle loss | Study design | Effects | Reference |
|---|---|---|---|
| AIDS | HMB/Arg/Gln mixture (3/14/14 g per day) for 8 weeks | ↑ lean body mass and improved immune status | Clark |
| Cancer | HMB/Arg/Gln mixture (3/14/14 g per day) for 24 weeks | ↑ body weight and FFM | May |
| Cancer | HMB/Arg/Gln mixture (3/14/14 g per day) for 8 weeks | Trend towards an increased body mass | Berk |
| AIDS or cancer | HMB/Arg/Gln mixture (3/14/14 g per day) for 8 weeks | Decreased feeling of weakness, increased RBC, haematocrit, lymphocytes, eosinophils, and urea | Rathmacher |
| Chronic obstructive pulmonary disease | HMB (3 g/day) for 7 days | Improved pulmonary function, ↓CRP | Hsieh |
| Chronic cardiac or pulmonary disease | Oral supplementation with proteins and HMB (1.5 g HMB/day) for 90 days | Decreased mortality, improved indices of nutritional status | Deutz |
| Chronic pulmonary disease | Oral supplementation with proteins and HMB (1.5 g HMB/day) for 12 weeks | Improved body composition, health‐related quality of life, and muscle strength | Olveira |
| Critically ill trauma patients, bed rest, enteral nutrition | HMB (3 g/day), HMB/Arg/Gln mixture or placebo via feeding tube for 28 days | Improvement in nitrogen balance | Kuhls |
| Total knee arthroplasty | HMB/Gln/Arg mixture (2.4/14/14 g per day) for 4 weeks | Prevention of reduction of maximal strength of quadriceps muscle | Nishizaki |
| Hip fracture | HMB (3 g)/vitamin D/protein combination for 30 days | Accelerated healing, shortening immobilization period, ↑ muscle strength | Ekinci |
| Gastric bypass | HMB/Gln/Arg mixture (1.5/7/7 g per day) for 8 weeks | No benefits when compared with controls | Clements |
| Renal failure | HMB (3 g/day) for 6 months | No benefits | Fitschen |
| Rheumatoid arthritis | HMB/Gln/Arg mixture (3/14/14 g per day) for 12 weeks | No benefits when compared with placebo | Marcora |